Literature DB >> 11508875

The effect of pars plana vitrectomy in the management of Fuchs heterochromic cyclitis.

R A Scott1, P M Sullivan, G W Aylward, C E Pavésio, D G Charteris.   

Abstract

PURPOSE: Fuchs heterochromic cyclitis (FHC) is characterized by a unilateral chronic iridocyclitis of insidious onset and uncertain cause. Our aim was to evaluate the effect of vitreous surgery in patients with FHC and clinically significant visual symptoms caused by inflammatory vitreous debris.
METHODS: This study was a review of 12 eyes of 12 consecutive patients with FHC who underwent pars plana vitrectomy for visually significant vitreous opacities. Cataract extraction with posterior chamber lens implantation had been performed on four eyes preoperatively. Four eyes had a concomitant lensectomy for cataracts, and one had a surgical posterior capsulotomy. Visual and anatomic data were recorded before surgery and for at least 6 months after surgery.
RESULTS: Visual acuity improved in all patients from an average logMAR of 0.57 to 0.007 (P = 0.0004) and by more than 2 Snellen lines in 8 of 12 of the eyes (P < 0.05). Symptoms of floaters resolved in all 11 patients in whom they were a symptom. Vitreous haze was cleared completely from an average Nussenblatt grade of 1.7 to 0 after 1 week (P = 0.0001).
CONCLUSIONS: Pars plana vitrectomy is a safe and effective treatment for the visual symptoms associated with FHC and can be combined safely with a lensectomy if required.

Entities:  

Mesh:

Year:  2001        PMID: 11508875     DOI: 10.1097/00006982-200108000-00003

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  6 in total

1.  Phacoemulsification and Core Vitrectomy in Fuchs' Heterochromic Uveitis.

Authors:  Sadullah Keles; Osman Ondas; Orhan Ates; Metin Ekinci; Baki Kartal; Eren Arpali; Kenan Yildirim; Erdinc Ceylan; Orhan Baykal
Journal:  Eurasian J Med       Date:  2017-06

2.  Is cyclophotocoagulation an option in the management of glaucoma secondary to Fuchs' uveitis syndrome?

Authors:  Bogomil Voykov; Christoph Deuter; Manfred Zierhut; Martin Alexander Leitritz; Emmanuella Guenova; Emmanuella Guenova-Hötzenecker; Deshka Doycheva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-01-05       Impact factor: 3.117

Review 3.  [Fuchs uveitis syndrome--heterochromia is no "conditio sine qua non"].

Authors:  M D Becker; M Zierhut
Journal:  Ophthalmologe       Date:  2005-07       Impact factor: 1.059

4.  Expression Profile of Intravitreous Cytokines, Chemokines and Growth Factors in Patients with Fuchs Heterochromic Iridocyclitis.

Authors:  Kaori Suzuki; Yukihiko Suzuki; Mitsuo Matsumoto; Mitsuru Nakazawa
Journal:  Case Rep Ophthalmol       Date:  2010-05-12

Review 5.  [Therapeutic vitrectomy in uveitis: current status and recommendations].

Authors:  M D Becker; N Harsch; M Zierhut; J L Davis; F G Holz
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

6.  Monoclonal immunoglobulin heavy chain gene rearrangement in Fuchs' uveitis.

Authors:  Hisae Nakahara; Toshikatsu Kaburaki; Rie Tanaka; Junko Matsuda; Mitsuko Takamoto; Kazuyoshi Ohtomo; Kimiko Okinaga; Keiko Komae; Jiro Numaga; Yujiro Fujino; Makoto Aihara
Journal:  BMC Ophthalmol       Date:  2018-03-09       Impact factor: 2.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.